Anti-CD45 pretargeted radioimmunotherapy using bismuth-213: high rates of complete remission and long-term survival in a mouse myeloid leukemia xenograft model

Pretargeted radioimmunotherapy (PRIT) using an anti-CD45 antibody (Ab)–streptavidin (SA) conjugate and DOTA-biotin labeled with β-emitting radionuclides has been explored as a strategy to decrease relapse and toxicity. α-emitting radionuclides exhibit high cytotoxicity coupled with a short path leng...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Pagel, John M., Kenoyer, Aimee L., Bäck, Tom, Hamlin, Donald K., Wilbur, D. Scott, Fisher, Darrell R., Park, Steven I., Frayo, Shani, Axtman, Amanda, Orgun, Nural, Orozco, Johnnie, Shenoi, Jaideep, Lin, Yukang, Gopal, Ajay K., Green, Damian J., Appelbaum, Frederick R., Press, Oliver W.
Formato: Artigo
Idioma:Inglês
Publicado: American Society of Hematology 2011
Assuntos:
Myeloid Neoplasia
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC3142907/
https://ncbi.nlm.nih.gov/pubmed/21613259
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2011-04-347039
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares